ASTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Astrana Health Inc (ASTH) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the stock shows bullish technical indicators, its overbought RSI and declining net income and EPS in the latest quarter suggest caution. Additionally, there are no significant trading signals or recent congress trading data to support an immediate buy decision.
The stock exhibits bullish momentum with MACD positively expanding, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a price near resistance levels (R1: 30.13, R2: 31.769). However, the RSI of 87.864 indicates the stock is overbought, suggesting a potential pullback.
The company is actively participating in investor conferences to enhance visibility and attract potential investors. Astrana Health supports a large provider and patient base, focusing on scalable, technology-enabled healthcare services to improve patient outcomes.
The latest quarter's financial performance shows a significant decline in net income (-186.30% YoY) and EPS (-180.00% YoY), raising concerns about profitability. Additionally, the stock is overbought, and there are no recent congress trading data or significant hedge fund/insider activity to support a strong buy.
In Q4 2025, revenue increased by 42.89% YoY to $950.53M, but net income dropped by -186.30% YoY to $5.99M, and EPS declined by -180.00% YoY to 0.12. Gross margin improved by 29.83% YoY to 8.27, indicating some operational efficiency gains.
Analysts maintain a positive outlook with recent price target increases from Baird ($40) and Truist ($38), citing the company's growth as a value-based care platform. However, BTIG lowered its price target to $40 from $45, citing macro challenges and investor concerns about guidance and earnings.
